Mycoses

Papers
(The H4-Index of Mycoses is 29. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
COVID‐19‐associated mucormycosis: An updated systematic review of literature187
ECMM/ISHAM recommendations for clinical management of COVID‐19 associated mucormycosis in low‐ and middle‐income countries143
Invasive pulmonary aspergillosis in the COVID‐19 era: An expected new entity141
The double‐edged sword of systemic corticosteroid therapy in viral pneumonia: A case report and comparative review of influenza‐associated mucormycosis versus COVID‐19 associated mucormycosis134
Increased incidence of candidemia in a tertiary care hospital with the COVID‐19 pandemic122
Mucormycosis and COVID‐19: An epidemic within a pandemic in India120
Mucormycosis in patients with COVID‐19: A cross‐sectional descriptive multicentre study from Iran103
Incidence and mortality of COVID‐19‐associated pulmonary aspergillosis: A systematic review and meta‐analysis78
Guideline: Vulvovaginal candidosis (AWMF 015/072, level S2k)76
Characteristics of candidemia in COVID‐19 patients; increased incidence, earlier occurrence and higher mortality rates compared to non‐COVID‐19 patients72
Prevalence of opportunistic invasive aspergillosis in COVID‐19 patients with severe pneumonia58
Epidemiology and Mycology of Candidaemia in non‐oncological medical intensive care unit patients in a tertiary center in the United States: Overall analysis and comparison between non‐COVID‐19 and COV53
Invasive aspergillosis in critically ill patients: Review of definitions and diagnostic approaches52
COVID‐19–associated pulmonary aspergillosis: a prospective single‐center dual case series47
Axillary Digital Thermometers uplifted a multidrug‐susceptible Candidaauris outbreak among COVID‐19 patients in Brazil45
Results from a national survey on COVID‐19‐associated mucormycosis in Germany: 13 patients from six tertiary hospitals42
Accuracy of galactomannan testing on tracheal aspirates in COVID‐19‐associated pulmonary aspergillosis42
Invasive dermatophyte infection: A systematic review41
Increased incidence of rhino‐orbital mucormycosis in an educational therapeutic hospital during the COVID‐19 pandemic in western Iran: An observational study39
Let's talk about sex characteristics—As a risk factor for invasive fungal diseases39
Global prevalence and subgroup analyses of coronavirus disease (COVID‐19) associated Candida auris infections (CACa): A systematic review and meta‐analysis38
Gut mycobiome: The probable determinative role of fungi in IBD patients35
Epidemiology of invasive fungal disease in haematologic patients34
Is there an association between zinc and COVID‐19–associated mucormycosis? Results of an experimental and clinical study34
Proven COVID‐19—associated pulmonary aspergillosis in patients with severe respiratory failure32
Molecular characterisation of Candida auris isolates from immunocompromised patients in a tertiary‐care hospital in Kuwait reveals a novel mutation in FKS1 conferring reduced susceptibil31
Prevalence, risk factors, treatment and outcome of multidrug resistance Candida auris infections in Coronavirus disease (COVID‐19) patients: A systematic review30
Mortality in critically ill patients with coronavirus disease 2019‐associated pulmonary aspergillosis: A systematic review and meta‐analysis29
Evaluation of DermaGenius® resistance real‐time polymerase chain reaction for rapid detection of terbinafine‐resistant Trichophyton species29
Talaromyces marneffei infection in non–HIV‐infected patients in mainland China29
0.055772066116333